What we found on the web about Alvimopan
Alvimopan (Entereg) is a drug which behaves as a peripherally acting μ-opioid antagonist. With limited ability to cross the blood-brain barrier, many of the undesirable side ...
You should not use this medication if you are allergic to alvimopan, or if you have used a narcotic medication within the past 7 days. You may be more likely to have unpleasant ...
MANAGED CARE July 2008. ©MediMedia USA Tomorrow’s Medicine Alvimopan Hastens Recovery From Abdominal Surgery Commercial and public payers concerned by prolonged hospital stays ...
PubMed is a service of the U.S. National Library of Medicine that includes over 18 million citations from MEDLINE and other life science journals for biomedical articles back to ...
Published Online, 2 August 2005, www.theannals.com, DOI 10.1345/aph.1E615. The Annals of Pharmacotherapy: Vol. 39, No. 9, pp. 1502-1510. DOI 10.1345/aph.1E615
FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE ENTEREG is indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel ...
Top of page Abstract. In May 2008, alvimopan (Entereg; Adolor/GlaxoSmithKline), a peripherally acting -opioid receptor antagonist, was approved by the US FDA to accelerate the time ...
Learn about the prescription medication Entereg Capsules (Alvimopan Capsules), drug uses, dosage, side effects, drug interactions, warnings, and patient labeling.
What is alvimopan? Alvimopan reduces certain side effects of narcotic medications that are often used to prevent pain caused by surgery. Narcotic medications can cause stomach pain ...
1: Expert Opin Investig Drugs. 2005 Apr;14(4):479-88. Alvimopan. Neary P, Delaney CP. Department of Colorectal Surgery/A-30, Cleveland Clinic Foundation, 9500 Euclid Avenue ...
Here is what users have to say about Alvimopan

Alvimopan (Entereg) is a drug which behaves as a peripherally acting μ-opioid antagonist. With limited ability to cross the blood-brain barrier, many of the undesirable side-effects of the opioid agonists such as constipation are minimized without affecting analgesia or precipitating withdrawals. The Food and Drug Administration reviewed the safety and efficacy data for alvimopan and approved its use in May 2008.

Welcome to CWAnswers

CWAnswers is your guide to the sprawling world wide web. The directory aims to provide a useful guide made by users. You can share your knowledge as well - simply register and edit your first entry. For questions just contact the team at support - at - cwanswers.com.

Weblinks

Top 10

Things you find nowhere else.

Comments

You must be logged in to post a comment.

No comments yet on this topic. Be the first one!